|
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study |
Feb 2025 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists |
Nov 2024 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
Mar 2025 |
Neoplasia |
Myelodysplastic Syndromes (MDS) |
|
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms |
Mar 2025 |
Archives of Pathology & Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Mar 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
Oct 2020 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
